Sabina Signoretti

List of Publications by Citations

253 papers	24,051 citations	76 h-index	153 g-index
265 ext. papers	28,698 ext. citations	11.5 avg, IF	6.25 L-index

#	Paper	IF	Citations
253	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
252	Renal cell carcinoma. *Nature Reviews Disease Primers*, **2017**, 3, 17009	51.1	963
251	High-throughput oncogene mutation profiling in human cancer. *Nature Genetics*, **2007**, 39, 347-51	36.3	847
250	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *New England Journal of Medicine*, **2016**, 374, 135-45	59.2	753
249	Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Research*, **2005**, 65, 3044-8	10.1	668
248	Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature*, **2008**, 454, 776-9	50.4	599
247	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discovery*, **2015**, 5, 1164-1177	24.4	581
246	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science*, **2018**, 359, 801-806	33.3	562
245	The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell*, **2014**, 26, 319-330	24.3	521
244	Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. *Molecular and Cellular Biology*, **2000**, 20, 8969-82	4.8	496
243	p63 is a prostate basal cell marker and is required for prostate development. *American Journal of Pathology*, **2000**, 157, 1769-75	5.8	470
242	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. *Nature*, **2011**, 470, 269-73	50.4	383
241	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discovery*, **2014**, 4, 1140-53	24.4	361
240	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. *Clinical Cancer Research*, **2005**, 11, 3714-21	12.9	358
239	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. *Nature*, **2002**, 419, 162-7	50.4	356
238	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Research*, **2009**, 69, 4674-81	10.1	327
237	Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. *Cell Metabolism*, **2014**, 19, 795-809	24.6	311

236	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295
235	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. *Journal of the National Cancer Institute*, **2009**, 101, 519-32	9.7	293
234	Genetic and functional studies implicate HIF1 as a 14q kidney cancer suppressor gene. *Cancer Discovery*, **2011**, 1, 222-35	24.4	283
233	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. *Cancer Cell* , **2004**, 5, 253-61	24.3	269
232	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nature Genetics*, **2018**, 50, 1271-1281	36.3	249
231	On-target efficacy of a HIF-2 antagonist in preclinical kidney cancer models. *Nature*, **2016**, 539, 107-111	50.4	249
230	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. *Nature Genetics*, **2011**, 43, 964-968	36.3	242
229	The requirement for cyclin D function in tumor maintenance. *Cancer Cell*, **2012**, 22, 438-51	24.3	234
228	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. *Cancer Discovery*, **2014**, 4, 546-53	24.4	224
227	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. *Nature Communications*, **2019**, 10, 1617	17.4	218
226	Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. *American Journal of Surgical Pathology*, **1997**, 21, 1307-15	6.7	206
225	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. *Cancer Immunology Research*, **2015**, 3, 1158-64	12.5	205
224	VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. *Nature Cell Biology*, **2008**, 10, 361-9	23.4	198
223	Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nature Genetics*, **2016**, 48, 725-32	36.3	193
222	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. *Oncotarget*, **2016**, 7, 34341-55	3.3	185
221	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 626-35	6.1	178
220	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *Journal of Clinical Oncology*, **2014**, 32, 1889-94	2.2	177
219	Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. *Cancer Research*, **2013**, 73, 2718-36	10.1	174

218	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. *Clinical Cancer Research*, **2015**, 21, 1071-7	12.9	173
217	BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. *Journal of Biological Chemistry*, **2000**, 275, 39223-30	5.4	166
216	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. *Science*, **2019**, 363, 1217-1222	33.3	165
215	The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. *Clinical Cancer Research*, **2010**, 16, 3628-38	12.9	165
214	Role of the Cdc25A phosphatase in human breast cancer. *Journal of Clinical Investigation*, **2000**, 106, 753-61	15.9	159
213	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8105-10	11.5	157
212	Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. *Clinical Genitourinary Cancer*, **2007**, 5, 379-85	3.3	156
211	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nature Medicine*, **2020**, 26, 909-918	50.5	155
210	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. *Nature Genetics*, **2018**, 50, 206-218	36.3	153
209	Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. *Cancer Research*, **2004**, 64, 8867-75	10.1	153
208	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2016**, 22, 2445-2452	12.9	150
207	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. *Cancer Cell*, **2008**, 14, 146-55	24.3	136
206	A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. *EMBO Molecular Medicine*, **2014**, 6, 519-38	12	134
205	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. *Cell*, **2016**, 166, 126-39	56.2	131
204	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. *Nature Genetics*, **2013**, 45, 747-55	36.3	121
203	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13379-86	11.5	121
202	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. *Science*, **2016**, 353, 929-32	33.3	120
201	p63 regulates commitment to the prostate cell lineage. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 11355-60	11.5	120

200	Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. *Cell*, **2013**, 155, 844-57	56.2	117
199	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. *Clinical Cancer Research*, **2015**, 21, 561-8	12.9	114
198	FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. *Cancer Cell*, **2010**, 18, 472-84	24.3	112
197	SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. *Cancer Cell*, **2013**, 24, 738-50	24.3	111
196	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. *Journal of Clinical Oncology*, **2016**, 34, 3655-3663	2.2	111
195	Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. *Cancer Discovery*, **2012**, 2, 1150-65	24.4	107
194	Reciprocal effects of STAT5 and STAT3 in breast cancer. *Molecular Cancer Research*, **2009**, 7, 966-76	6.6	107
193	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. *Journal of Clinical Investigation*, **2002**, 110, 633-41	15.9	106
192	Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. *Circulation*, **2010**, 122, 1004-16	16.7	102
191	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. *Nature Genetics*, **2013**, 45, 739-746	36.3	100
190	Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. *Modern Pathology*, **2002**, 15, 1302-8	9.8	99
189	A working group classification of focal prostate atrophy lesions. *American Journal of Surgical Pathology*, **2006**, 30, 1281-91	6.7	97
188	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. *Cancer Immunology Research*, **2015**, 3, 1308-15	12.5	96
187	Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. *Radiology*, **2009**, 251, 731-42	20.5	93
186	Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. *Oncogene*, **2002**, 21, 4099-107	9.2	92
185	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nature Communications*, **2019**, 10, 4346	17.4	89
184	The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. *Clinical Cancer Research*, **2007**, 13, 758s-763s	12.9	86
183	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. *Cancer Research*, **2002**, 62, 89-98	10.1	86

182	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. *Nature Medicine*, **2018**, 24, 165-175	50.5	85
181	Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. *American Journal of Clinical Pathology*, **2010**, 134, 873-9	1.9	82
180	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. *European Urology*, **2017**, 72, 557-564	10.2	81
179	Intermediate basal cells of the prostate: in vitro and in vivo characterization. *Prostate*, **2003**, 55, 206-18	4.2	81
178	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. *Cancer Discovery*, **2017**, 7, 750-765	24.4	77
177	BRAF mutations in metanephric adenoma of the kidney. *European Urology*, **2012**, 62, 917-22	10.2	76
176	Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. *Radiology*, **2005**, 235, 469-77	20.5	76
175	Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. *Cancer Discovery*, **2014**, 4, 896-904	24.4	75
174	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. *BJU International*, **2010**, 106, 772-8	5.6	73
173	Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. *American Journal of Pathology*, **1999**, 154, 67-75	5.8	73
172	Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. *Molecular Endocrinology*, **2001**, 15, 765-82		70
171	Estrogen receptor beta in prostate cancer: brake pedal or accelerator?. *American Journal of Pathology*, **2001**, 159, 13-6	5.8	68
170	Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. *Radiology*, **2010**, 255, 62-74	20.5	67
169	Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. *Cancer Discovery*, **2019**, 9, 230-247	24.4	67
168	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. *Cancer Immunology Research*, **2018**, 6, 758-765	12.5	66
167	Androgen-dependent regulation of Her-2/neu in prostate cancer cells. *Cancer Research*, **2006**, 66, 5723-8	10.1	66
166	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. *Clinical Cancer Research*, **2013**, 19, 5218-26	12.9	65
165	Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. *Radiology*, **2007**, 244, 464-70	20.5	65

164	Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. *Molecular and Cellular Biology*, **2002**, 22, 635-43	4.8	65
163	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. *Journal of Clinical Oncology*, **2020**, 38, 63-70	2.2	64
162	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study **2015**, 3, 3		63
161	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. *PLoS Genetics*, **2016**, 12, e1006242	6	62
160	Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. *American Journal of Roentgenology*, **2008**, 191, 133-9	5.4	61
159	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 78-86	12.9	60
158	Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. *PLoS ONE*, **2011**, 6, e19144	3.7	59
157	p63 in prostate biology and pathology. *Journal of Cellular Biochemistry*, **2008**, 103, 1354-68	4.7	58
156	Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. *Molecular Cancer Therapeutics*, **2010**, 9, 2793-802	6.1	57
155	A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 11002-7	11.5	54
154	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. *Cancer Cell*, **2021**, 39, 649-661.e5	24.3	54
153	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. *Cancer*, **2015**, 121, 3435-43	6.4	53
152	Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. *Modern Pathology*, **2001**, 14, 437-42	9.8	53
151	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 1247-1255	13.4	51
150	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. *Cancer Cell*, **2014**, 26, 222-34	24.3	51
149	The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. *Molecular Cell*, **2012**, 46, 67-78	17.6	51
148	Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. *Radiology*, **2005**, 235, 81-8	20.5	50
147	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. *Clinical Cancer Research*, **2015**, 21, 1925-1934	12.9	48

146	Identification of CDCP1 as a hypoxia-inducible factor 2 (HIF-2) target gene that is associated with survival in clear cell renal cell carcinoma patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 3483-8	11.5	48
145	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. *Clinical Cancer Research*, **2019**, 25, 2174-2184	12.9	47
144	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. *Lancet Oncology, The*, **2013**, 14, 81-7	21.7	46
143	Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. *Journal of Cutaneous Pathology*, **2000**, 27, 228-34	1.7	45
142	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. *Oncologist*, **2017**, 22, 286-292	5.7	44
141	Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. *International Journal of Hyperthermia*, **2011**, 27, 527-38	3.7	44
140	Melanocytic nevi of palms and soles: a histological study according to the plane of section. *American Journal of Surgical Pathology*, **1999**, 23, 283-7	6.7	44
139	Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?. *Radiology*, **2010**, 257, 685-96	20.5	43
138	Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. *Radiology*, **2006**, 240, 82-9	20.5	42
137	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. *Cancer Cell*, **2021**, 39, 632-648.e8	24.3	42
136	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman disease. *Journal of Pathology*, **2001**, 193, 200-9	9.4	41
135	Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. *Cancer Discovery*, **2013**, 3, 44-51	24.4	40
134	Defining cell lineages in the prostate epithelium. *Cell Cycle*, **2006**, 5, 138-41	4.7	40
133	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 10238-43	11.5	39
132	Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. *Oncotarget*, **2016**, 7, 29901-15	3.3	39
131	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. *Scientific Reports*, **2016**, 6, 27702	4.9	38
130	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clinical Cancer Research*, **2014**, 20, 1873-83	12.9	38
129	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1788-93	2.8	37

128	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. *Molecular Cancer*, **2015**, 14, 119	42.1	35
127	Risk of bilateral renal cell cancer. *Journal of Clinical Oncology*, **2009**, 27, 3737-41	2.2	35
126	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. *Clinical Genitourinary Cancer*, **2016**, 14, e25-36	3.3	34
125	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. *Clinical Cancer Research*, **2019**, 25, 6080-6088	12.9	33
124	RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. *Molecular Cancer Research*, **2015**, 13, 130-7	6.6	32
123	Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. *Surgical Pathology Clinics*, **2015**, 8, 587-621	3.9	32
122	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. *Journal of Pathology*, **2011**, 225, 212-21	9.4	32
121	Tissue biomarkers in renal cell carcinoma: issues and solutions. *Cancer*, **2009**, 115, 2290-7	6.4	31
120	GRK3 is essential for metastatic cells and promotes prostate tumor progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1521-6	11.5	30
119	Prostate stem cells: from development to cancer. *Seminars in Cancer Biology*, **2007**, 17, 219-24	12.7	30
118	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. *Genes and Development*, **2019**, 33, 1718-1738	12.6	29
117	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. *British Journal of Cancer*, **2020**, 122, 555-563	8.7	28
116	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. *Journal of Clinical Oncology*, **2018**, JCO2018792259	2.2	28
115	Treatment selection for patients with metastatic renal cell carcinoma. *Cancer*, **2009**, 115, 2327-33	6.4	27
114	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 820-4	7.3	26
113	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. *Journal of Clinical Oncology*, **2020**, 38, 5006-5006	2.2	26
112	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. *Nature Communications*, **2021**, 12, 808	17.4	26
111	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. *Science Signaling*, **2019**, 12,	8.8	25

110	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. *British Journal of Cancer*, **2018**, 118, 1238-1242	8.7	25
109	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2 *European Journal of Cancer*, **2014**, 50, 1531-40	7.5	25
108	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. *Clinical Genitourinary Cancer*, **2016**, 14, e585-e594	3.3	24
107	HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. *Science Translational Medicine*, **2017**, 9,	17.5	24
106	D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. *Developmental Cell*, **2014**, 30, 255-67	10.2	22
105	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. *Journal of Urology*, **2017**, 198, 817-823	2.5	21
104	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. *Cancer Immunology Research*, **2020**, 8, 1075-1084	12.5	21
103	Tissue-based research in kidney cancer: current challenges and future directions. *Clinical Cancer Research*, **2008**, 14, 3699-705	12.9	20
102	p63 promotes cell survival through fatty acid synthase. *PLoS ONE*, **2009**, 4, e5877	3.7	20
101	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. *Cancer Immunology Research*, **2021**, 9, 156-169	12.5	20
100	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. *Future Oncology*, **2019**, 15, 1683-1695	3.6	19
99	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. *Histopathology*, **2015**, 66, 901-4	7.3	19
98	Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. *Diagnostic Molecular Pathology*, **2002**, 11, 187-92		19
97	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. *Journal of Clinical Oncology*, **2019**, 37, 548-548	2.2	19
96	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. *Oncotarget*, **2016**, 7, 41857-41869	3.3	19
95	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. *Cancer Discovery*, **2015**, 5, 550-63	24.4	18
94	MET as a target in papillary renal cell carcinoma. *Clinical Cancer Research*, **2014**, 20, 3361-3	12.9	18
93	Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. *Journal of Investigative Dermatology*, **2007**, 127, 106-15	4.3	18

92	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 1371-1380	12.9	18
91	Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. *Journal of Cutaneous Pathology*, **2004**, 31, 477-82	1.7	17
90	Pml represses tumour progression through inhibition of mTOR. *EMBO Molecular Medicine*, **2011**, 3, 249-57	8.2	15
89	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. *Oncotarget*, **2017**, 8, 103428-103436	3.3	13
88	RET protein expression in papillary renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 900-5	2.8	12
87	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. *BJU International*, **2008**, 101 Suppl 4, 31-5	5.6	12
86	p63+ ureteric bud tip cells are progenitors of intercalated cells. *JCI Insight*, **2017**, 2,	9.9	12
85	Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. *Human Pathology*, **2015**, 46, 384-9	3.7	11
84	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. *Cancer Cytopathology*, **2015**, 123, 696-706	3.9	10
83	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, 304-313.e6	3.3	10
82	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. *Cancer*, **2016**, 122, 2389-98	6.4	9
81	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. *European Urology Focus*, **2016**, 2, 633-639	5.1	9
80	Loss of LDAH associated with prostate cancer and hearing loss. *Human Molecular Genetics*, **2018**, 27, 4194-4203	5.6	9
79	Identification of ALK gene alterations in urothelial carcinoma. *PLoS ONE*, **2014**, 9, e103325	3.7	8
78	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2016**, 34, 545-545	2.2	8
77	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. *Journal of Clinical Oncology*, **2019**, 37, 4583-4583	2.2	8
76	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. *Journal of Clinical Oncology*, **2020**, 38, 5024-5024	2.2	8
75	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma **2020**, 8,		8

74	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. *Science Translational Medicine*, **2021**, 13,	17.5	8
73	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. *PLoS Genetics*, **2018**, 14, e1007679	6	8
72	Renal-cell carcinoma: a step closer to a new classification. *Lancet Oncology, The*, **2013**, 14, 105-7	21.7	7
71	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2017**, 23, 2159-2168	12.9	7
70	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. *Journal of Clinical Oncology*, **2017**, 35, TPS4596-TPS4596	2.2	7
69	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. *Journal of Clinical Oncology*, **2017**, 35, 477-477	2.2	7
68	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. *Molecular Cancer Therapeutics*, **2020**, 19, 690-696	6.1	7
67	Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E3741-E3748	11.5	6
66	Cell kinetic studies fail to identify sequentially proliferating progenitors as the major source of epithelial renewal in the adult murine prostate. *PLoS ONE*, **2015**, 10, e0128489	3.7	6
65	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. *Clinical Proteomics*, **2009**, 5, 37-45	5	6
64	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. *Journal of Clinical Oncology*, **2020**, 38, 5023-5023	2.2	6
63	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. *Clinical Cancer Research*, **2021**, 27, 4836-4847	12.9	6
62	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2019**, 37, 4514-4514	2.2	5
61	Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 2868-2878	12.9	5
60	Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma. *Journal of Virology*, **2011**, 85, 5581-92	6.6	4
59	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. *Journal of Clinical Oncology*, **2019**, 37, 103-103	2.2	4
58	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. *Journal of Clinical Oncology*, **2019**, 37, 4568-4568	2.2	4
57	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. *Journal of Clinical Oncology*, **2019**, 37, TPS684-TPS684	2.2	4

56	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. *Journal of Clinical Oncology*, **2020**, 38, 5002-5002	2.2	4
55	Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. *Cancer Immunology, Immunotherapy*, **2016**, 65, 1523-1532	7.4	4
54	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2018**, 16, 341-348	3.3	4
53	Integrative clinical and molecular characterization of translocation renal cell carcinoma.. *Cell Reports*, **2022**, 38, 110190	10.6	3
52	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. *Journal of Clinical Oncology*, **2019**, 37, TPS4597-TPS4597	2.2	3
51	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. *Journal of Clinical Oncology*, **2020**, 38, e19321-e19321	2.2	3
50	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. *BMC Cancer*, **2021**, 21, 904	4.8	3
49	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman disease **2001**, 193, 200		3
48	Anti-CAIX BB-CAR4/8 T-cells exhibit superior efficacy in a ccRCC mouse model.. *Molecular Therapy - Oncolytics*, **2022**, 24, 385-399	6.4	2
47	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 408-408	2.2	2
46	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. *Journal of Clinical Oncology*, **2018**, 36, 619-619	2.2	2
45	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. *Journal of Clinical Oncology*, **2020**, 38, 5010-5010	2.2	2
44	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2020**, 38, 715-715	2.2	2
43	Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2017**, 35, 434-434	2.2	2
42	Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma		2
41	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. *Journal of Clinical Oncology*, **2022**, 40, 352-352	2.2	2
40	Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2120403119	11.5	2
39	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. *Cancer Research*, **2021**,	10.1	2

38	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).. *Journal of Clinical Oncology*, **2022**, JCO2102938	2.2	2
37	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. *Human Pathology: Case Reports*, **2018**, 11, 19-20	0.2	1
36	Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.. *Journal of Clinical Oncology*, **2013**, 31, 370-370	2.2	1
35	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. *Journal of Clinical Oncology*, **2015**, 33, 4519-4519	2.2	1
34	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. *Journal of Clinical Oncology*, **2015**, 33, 405-405	2.2	1
33	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2015**, 33, 422-422	2.2	1
32	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. *Journal of Clinical Oncology*, **2016**, 34, e23221-e23221	2.2	1
31	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. *Journal of Clinical Oncology*, **2016**, 34, 485-485	2.2	1
30	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. *Journal of Clinical Oncology*, **2016**, 34, 501-501	2.2	1
29	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. *Journal of Clinical Oncology*, **2017**, 35, 4573-4573	2.2	1
28	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 513-513	2.2	1
27	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. *Journal of Clinical Oncology*, **2018**, 36, TPS710-TPS710	2.2	1
26	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. *Journal of Clinical Oncology*, **2020**, 38, TPS765-TPS765	2.2	1
25	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. *Journal of Clinical Oncology*, **2020**, 38, 740-740	2.2	1
24	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. *Journal of Clinical Oncology*, **2021**, 39, TPS4596-TPS4596	2.2	1
23	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. *JCO Precision Oncology*, **2022**, 6, e2100448	3.6	1
22	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.. *Journal of Clinical Oncology*, **2022**, 40, 288-288	2.2	1
21	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.. *Clinical Cancer Research*, **2021**,	12.9	1

20	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. *Clinical Cancer Research*, **2021**,	12.9	1
19	Uncommon Tumors of the Kidney **2017**, 19-40		0
18	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. *Journal of Clinical Oncology*, **2018**, 36, 626-626	2.2	0
17	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. *Journal of Clinical Oncology*, **2020**, 38, TPS5101-TPS5101	2.2	0
16	Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. *Clinical Cancer Research*, **2019**, 25, 4194	12.9	
15	In Reply. *Oncologist*, **2017**, 22, 1561	5.7	
14	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. *Journal of Clinical Oncology*, **2020**, 38, 729-729	2.2	
13	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. *Journal of Clinical Oncology*, **2018**, 36, 679-679	2.2	
12	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. *Journal of Clinical Oncology*, **2018**, 36, TPS4597-TPS4597	2.2	
11	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2019**, 37, 4582-4582	2.2	
10	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. *Journal of Clinical Oncology*, **2015**, 33, 4560-4560	2.2	
9	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. *Journal of Clinical Oncology*, **2016**, 34, 616-616	2.2	
8	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. *Journal of Clinical Oncology*, **2016**, 34, 4535-4535	2.2	
7	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. *Journal of Clinical Oncology*, **2017**, 35, 4576-4576	2.2	
6	Adult Prostate Epithelium Renewal, Stem Cells and Cancer **2009**, 231-246		
5	Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC **2012**, 69-89		
4	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2013**, 31, 260-260	2.2	
3	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. *Journal of Clinical Oncology*, **2013**, 31, 278-278	2.2	

2	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 387-387	2.2
1	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. *Journal of Clinical Oncology*, **2022**, 40, 569-569	2.2